Saturday, February 11, 2017
PetLife Pharmaceuticals Producing Cancer Drug From Venom Of The Caribbean Blue Scorpion.
PetLife Pharmaceuticals, Inc a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets. PetLife Pharmaceuticals, Inc., (OTC:PTLF) is launching a new generation of all natural veterinary cancer medications and nutraceuticals, based on the venom of the Caribbean Blue Scorpion. This treatment is based on the same patented formula and production processes used in the human formulation known as Escozine™. PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology—with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. WHAT IS VITALZUL™? see more